Latest News and Press Releases

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...

Amryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021 DUBLIN, Ireland, and Boston MA, February 24, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical...

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel DUBLIN, Ireland, and Boston MA, February 4, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...

Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales DUBLIN, Ireland, and Boston MA, January 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global,...

Amryt Granted Orphan Drug Designation by the FDA for AP103 DUBLIN, Ireland, and Boston MA, December 23, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company...

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia DUBLIN, Ireland, and Boston MA, December 17, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global,...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil DUBLIN, Ireland, and Boston MA, December 09, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...

Amryt Announces $40m Private Placement with Leading Biotech Investors DUBLIN, Ireland, and Boston MA, December 8, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...